2363. Three-Month Safety and Immunogenicity of Bivalent SARS-CoV-2 Omicron-Containing Booster Vaccines: Interim Results From a Phase 3, Randomized, Observer-Blind, Active-Controlled Trial

BACKGROUND: Updated COVID-19 vaccines have been developed to help broaden protection against circulating SARS-CoV-2 variants. Here we present a 3-month interim analysis from a phase 3, randomized, observer-blind, active-controlled study of 2 omicron BA.1-containing vaccines: BA.1-monovalent mRNA-127...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Ivan T, Cosgrove, Catherine A, Moore, Patrick, Bula, Marcin, Kalra, Philip, Dargan, Paul, Clark, Rebecca, Boffito, Marta, Sheridan, Ray, Bethune, Claire, Burns, Fiona, Saralaya, Dinesh, Nally, Rhiannon, Duncan, Christopher J A, Chadwick, David, Palfreeman, Adrian, Ramos, Alberto San Francisco, Heath, Paul T, Girard, Bethany, Sellers, Kristen, de Windt, Elizabeth, Sutherland, Andrea, Tracy, LaRee, Zhou, Honghong, Miller, Jacqueline, Priddy, Frances, Chalkias, Spyros, Das, Rituparna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677689/
http://dx.doi.org/10.1093/ofid/ofad500.1984

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677689/
http://dx.doi.org/10.1093/ofid/ofad500.1984

Ejemplares similares